Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Non-Current Assets (2019 - 2025)

Cyclerion Therapeutics has reported Non-Current Assets over the past 7 years, most recently at $5.4 million for Q3 2025.

  • Quarterly results put Non-Current Assets at $5.4 million for Q3 2025, changed 0.0% from a year ago — trailing twelve months through Sep 2025 was $21.4 million (changed 0.0% YoY), and the annual figure for FY2024 was $5.4 million, changed 0.0%.
  • Non-Current Assets for Q3 2025 was $5.4 million at Cyclerion Therapeutics, roughly flat from $5.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CYCN hit a ceiling of $55.5 million in Q1 2021 and a floor of $2.7 million in Q2 2021.
  • Median Non-Current Assets over the past 5 years was $5.4 million (2023), compared with a mean of $7.1 million.
  • Biggest five-year swings in Non-Current Assets: crashed 95.99% in 2021 and later skyrocketed 79.29% in 2024.
  • Cyclerion Therapeutics' Non-Current Assets stood at $3.9 million in 2021, then dropped by 15.88% to $3.3 million in 2022, then soared by 64.16% to $5.4 million in 2023, then changed by 0.0% to $5.4 million in 2024, then changed by 0.0% to $5.4 million in 2025.
  • The last three reported values for Non-Current Assets were $5.4 million (Q3 2025), $5.4 million (Q2 2025), and $5.4 million (Q1 2025) per Business Quant data.